<DOC>
	<DOC>NCT01578174</DOC>
	<brief_summary>The investigators examined the effect of dexmedetomidine in the management of pain after uterine artery embolization.</brief_summary>
	<brief_title>The Effect of Dexmedetomidine in the Management of Pain After Uterine Artery Embolization</brief_title>
	<detailed_description>Leiomyoma are the most common female reproductive tract tumors. Uterine artery embolization(UAE) is a minimally invasive treatment alternative to hysterectomy and myomectomy. However, post-procedural pain control after UAE remains a major problem. Therefore, the aim of study is to evaluate the efficacy of dexmedetomidine in pain control after UAE.</detailed_description>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>age ≥ 20, ASA class I and II bradycardia (&lt; 45 bpm) heart block liver failure renal failure uncontrolled hypertension body mass index ≥ 30 kg/m2</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>